| Literature DB >> 36071442 |
Taylor Do1, Lilly Synan1, Gibran Ali1, Heather Gappa-Fahlenkamp2.
Abstract
Small airway infections caused by respiratory viruses are some of the most prevalent causes of illness and death. With the recent worldwide pandemic due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is currently a push in developing models to better understand respiratory diseases. Recent advancements have made it possible to create three-dimensional (3D) tissue-engineered models of different organs. The 3D environment is crucial to study physiological, pathophysiological, and immunomodulatory responses against different respiratory conditions. A 3D human tissue-engineered lung model that exhibits a normal immunological response against infectious agents could elucidate viral and host determinants. To create 3D small airway lung models in vitro, resident epithelial cells at the air-liquid interface are co-cultured with fibroblasts, myeloid cells, and endothelial cells. The air-liquid interface is a key culture condition to develop and differentiate airway epithelial cells in vitro. Primary human epithelial and myeloid cells are considered the best 3D model for studying viral immune responses including migration, differentiation, and the release of cytokines. Future studies may focus on utilizing bioreactors to scale up the production of 3D human tissue-engineered lung models. This review outlines the use of various cell types, scaffolds, and culture conditions for creating 3D human tissue-engineered lung models. Further, several models used to study immune responses against respiratory viruses, such as the respiratory syncytial virus, are analyzed, showing how the microenvironment aids in understanding immune responses elicited after viral infections.Entities:
Keywords: Endothelial cells; Epithelial cells; Myeloid cells; Respiratory syncytial virus; Scaffolds; Tissue-engineered lung model
Mesh:
Year: 2022 PMID: 36071442 PMCID: PMC9449944 DOI: 10.1186/s13287-022-03134-1
Source DB: PubMed Journal: Stem Cell Res Ther ISSN: 1757-6512 Impact factor: 8.079
Fig. 1Immune responses to RSV infection. Infection of RSV particle causes the release of cytokines and chemokines, resulting in recruitment of immune cells. Chemokines released from alveolar type 2 (AT2) cells signal for natural killer (NK) cells and polymorphonuclear (PMN) leukocytes to kill infected cells as part of a nonspecific immune response. AT2 cells also release TNF-α, IL-6, IL-8, and IL-1β, causing activation of dendritic cells and macrophages and the recruitment of CD4+ T cells. These T cells release interferons (IFNs) that activate macrophages and help activate B cells which are required for the development of RSV antibodies. CD4+ T cells also recruit neutrophils from the blood to alveolar air spaces
Comparison of epithelial cells used in 3D tissue models to study viruses
| Source | Pathogen | Cytokine/protein expression | Infectivity | References |
|---|---|---|---|---|
| Human primary small airway | Influenza A | Aqp5−, CK-14+, SP-C−, IL-1β++, IL-6++, IL-8++, IL-10+, MCP-1− | Not measured | [ |
| Human primary ATI and ATII | Influenza A | IFN-β+, IL-6+, RANTES+, MCP-1+, IP-10+ | ATI—H5N1 and H1N1: ~ 105 TCID50/mL (48 h peak) ATII—H5N1 and H1N1: ~ 106 TCID50/mL (72 h peak) | [ |
| NHBE | HRV-C HBoV | TNF-α+, IP-10+, IL-6+, IL-8+ | Not measured | [ |
| Calu-3 | RSV HRV 14, 16 | RANTES+ Without PBMC: FGF-Basic+, IL-15+*, IP-10+, IL-6+, ENA-78+, MIP-1β− With PBMC: FGF-Basic+, IL-15+*, IP-10+, IL-6+, MIP-1β+*, IFN-α+*, MCP-2+, IL-28A+*, ENA-78+ | 106 RSV-A genome copies/mL (Peak on day 15) HRV 16: 0.04 1/Ct (peak on day 4) HRV 14: 0.07 1/Ct (peak on day 5) | [ |
| 16HBE14o− | ANDV | IP10+, IL-6+, IL-8+, RANTES− | 50,000 FFU/mL (peak on day 15) | [ |
| HCC38 | MV | Not measured | 100% GFP + epithelial cells four days p.i | [ |
| A549 | LPS IAV | IL-6+, IL-8+ IL-29++ | Not measured ~ 1 × 107pfu/mL IAV titer at 24 h p.i | [ [ |
AQP5, aquaporin5; CK-14, cytokeratin-14; SP-C, surfactant protein-C; IL, interleukin; MCP, monocyte chemoattractant protein; IFN, interferon; RANTES, regulated on activation, normal T cell expressed and secreted; IP-10, interferon gamma-induced protein-10; HRV-C, human rhinovirus-C; TNF-α, tumor necrosis factor-α; HBoV, human bocavirus; RSV, respiratory syncytial virus; Calu-3, cellosaurus cell line; PBMC, peripheral blood mononuclear cell; FGF, fibroblast growth factor; ENA, epithelial neutrophil-activating protein; MIP, macrophage inflammatory protein; ANDV, andes orthohantavirus; HBE14o, human bronchial epithelial cell line isolated; MV, measles morbillivirus; LPS, lipopolysaccharides; IAV, influenza A virus; PFU, plaque-forming unit
± = significant difference (P < 0.05) from control group; +±− = highly significant difference (P < 0.001) from control group, +* = HRV 14 only
Fig. 2Schematic presentation of three-dimensional in vitro lung tissue models to mimic immune responses following RSV infection. A Developing a 3D model within a hanging cell culture inserts with a porous membrane allows for nutrient exchange when exposed to air–liquid interface. Epithelial cells grow on the surface of the membrane and form tight junctions, while immune cells such as polymorphonuclear (PMN) leukocytes remain submerged. B Flow bioreactors using small airway epithelial cells (SAEC) to grow tissue aggregates infected with viruses. The release of cytokines and chemokines can be measured from the collected media